4 unknown, 2 not yet recruiting, 1 recruiting. 3 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Unknown 2, Recruiting 1 |
| Phase 2 | 3 | Unknown 2, Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Tarapeutics Science Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TR115 in ARID1A-Mutated Advanced Solid Tumors TR115 - Ovarian Clear Cell Carcinoma, Endometrial Cancer | Phase 2 | Not yet recruiting | Tarapeutics Science Inc. | 50 | 2026-09-20 | 2026-08-28 |
| TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma TR115, Investigator's Choice - PTCL, NK T-Cell Lymphoma | Phase 3 | Not yet recruiting | Tarapeutics Science Inc. | 180 | 2026-07-30 | 2026-06-10 |
| TR128 in Patients With Advanced Solid Tumors TR128 - Advanced Solid Tumor | Phase 1 | Unknown | Tarapeutics Science Inc. | 50 | 2024-02-23 | 2024-05-14 |
| TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors TR115 - Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory | Phase 1 | Unknown | Tarapeutics Science Inc. | 26 | 2023-04-23 | 2024-05-14 |
| TR64 in Patients With Advanced Solid Tumors TR64 - Advanced Solid Tumor | Phase 1 | Recruiting | Tarapeutics Science Inc. | 19 | 2023-01-12 | 2024-05-14 |
| A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) HYML-122; cytarabine - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 2 | Unknown | Tarapeutics Science Inc. | 18 | 2022-03-29 | 2025-04-10 |
| A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) HYML-122 - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 2 | Unknown | Tarapeutics Science Inc. | 15 | 2021-09-29 | 2024-05-14 |
Recurrence (3) · Leukemia, Myeloid, Acute (2) · Endometrial Neoplasms (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Non-Hodgkin (1) · Urinary Bladder Neoplasms (1)
Cytarabine (1)
China (7)
Depei Wu, MD. PhD (2) · Funan Liu, MD, PhD (1) · Huan Zhou, PhD (1) · Jie Jin, MD, PhD (1) · Lin Shen, MD, PhD (1)